This site is intended for healthcare professionals

Cytokinetics regains rights to to omecamtiv mecarbil, a proposed treatment for heart failure and to AMG 594 from Amgen.

Read time: 1 mins
Last updated:24th Nov 2020
Published:24th Nov 2020
Condition: Heart Failure
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest